WAKE FOREST UNIVERSITY HEALTH SCIENCES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

Not Applicable

Terminated

Conditions: Chemotherapy-induced Peripheral Neuropathy
Plasma Cell Myeloma

Interventions: Device: VascuTherm5 vascular compression device

First Posted Date: 2019-03-12

Last Posted Date: 2024-10-26

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 18

Registration Number: NCT03870451

Locations: 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma

Phase 2

Terminated

Conditions: Glioma
Glioblastoma

Interventions: Drug: Soliramfetol

First Posted Date: 2019-03-11

Last Posted Date: 2024-12-24

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 2

Registration Number: NCT03868943

Locations: 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

The Effects of MAP and EtCO2 on Venous Sinus Pressures

Not Applicable

Completed

Conditions: Idiopathic Intracranial Hypertension

Interventions: Procedure: Venous Sinus Stenting
Other: Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)
Other: Adjustment to Mean Arterial Pressure (60-80 mmHg range)
Other: Adjustment to Mean Arterial Pressure (100-110 mmHg range)
Other: Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)

First Posted Date: 2019-03-08

Last Posted Date: 2020-05-12

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 8

Registration Number: NCT03867461

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Liposomal Bupivacaine (Exparel) in Sarcomas

Early Phase 1

Terminated

Conditions: Soft Tissue Sarcoma
Soft Tissue Tumor
Soft Tissue Tumor and/or Sarcoma

Interventions: Drug: Liposomal Bupivacaine

First Posted Date: 2019-03-07

Last Posted Date: 2023-03-22

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 2

Registration Number: NCT03867188

Locations: 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Improving Morbidity During Post-Acute Care Transitions for Sepsis

Not Applicable

Completed

Conditions: Clinical Sepsis

Interventions: Behavioral: Sepsis Transition And Recovery (STAR)
Behavioral: Usual care

First Posted Date: 2019-03-07

Last Posted Date: 2022-04-25

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 712

Registration Number: NCT03865602

Locations: 🇺🇸
Atrium Health, Charlotte, North Carolina, United States

Epigenetic and Metabolomic Changes in Childhood Cancer Survivors

Terminated

Conditions: Childhood Cancer

First Posted Date: 2019-03-07

Last Posted Date: 2023-12-20

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 7

Registration Number: NCT03866707

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Metastatic Lung Cancer
Stage IV Lung Cancer

Interventions: Radiation: Stereotactic Body Radiation Therapy
Biological: Pembrolizumab

First Posted Date: 2019-03-07

Last Posted Date: 2024-03-15

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 5

Registration Number: NCT03867175

Locations: 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

No Drop Post-Op Cataract Surgery

Phase 4

Completed

Conditions: Cataract

Interventions: Drug: Omidria

First Posted Date: 2019-03-06

Last Posted Date: 2023-11-30

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 94

Registration Number: NCT03864133

Locations: 🇺🇸
Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States

Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT

Phase 2

Completed

Conditions: Lung Neoplasm

Interventions: Drug: Matching placebo
Drug: risedronate

First Posted Date: 2019-03-04

Last Posted Date: 2023-07-27

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 84

Registration Number: NCT03861091

Locations: 🇺🇸
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸
High Point Regional Medical Center, High Point, North Carolina, United States

Secondary Versus Tertiary Wound Closure in High Risk Gynecologic Abdominal Surgical Incisions

Not Applicable

Terminated

Conditions: Surgical Incision

Interventions: Procedure: Historical Wound Closure
Procedure: Tertiary Wound Closure

First Posted Date: 2019-03-04

Last Posted Date: 2024-07-03

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 8

Registration Number: NCT03861065

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy